NASDAQ:RCEL Avita Medical (RCEL) Stock Price, News & Analysis $4.37 +0.26 (+6.33%) Closing price 04:00 PM EasternExtended Trading$4.42 +0.05 (+1.10%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avita Medical Stock (NASDAQ:RCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avita Medical alerts:Sign Up Key Stats Today's Range$4.11▼$4.4750-Day Range$3.63▼$5.6052-Week Range$3.22▼$7.43Volume433,706 shsAverage Volume201,259 shsMarket Capitalization$134.51 millionP/E RatioN/ADividend YieldN/APrice Target$6.63Consensus RatingHold Company Overview Avita Medical, Inc. (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures. Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S. Food and Drug Administration for acute thermal burn wounds. The company has since expanded its clinical indications and market access efforts into regions such as Australia, China and other parts of Asia. Avita collaborates with leading burn centers, academic institutions and investigator‐initiated trials to explore additional applications—ranging from chronic diabetic ulcers to vitiligo and hair restoration. Under the leadership of President and Chief Executive Officer Michael Perry, Avita Medical has emphasized the integration of its proprietary cell‐harvesting technology into standard burn and wound care protocols. The company maintains a global commercial infrastructure to support physician training, clinical research, and post‐market surveillance. Its strategic priorities include broadening clinical adoption of ReCell, pursuing new regulatory approvals and fostering partnerships to extend its regenerative platform into adjacent markets.AI Generated. May Contain Errors. Read More Avita Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreRCEL MarketRank™: Avita Medical scored higher than 56% of companies evaluated by MarketBeat, and ranked 374th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingAvita Medical has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAvita Medical has a consensus price target of $6.63, representing about 51.6% upside from its current price of $4.37.Amount of Analyst CoverageAvita Medical has only been the subject of 3 research reports in the past 90 days.Read more about Avita Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avita Medical are expected to grow in the coming year, from ($1.23) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avita Medical is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avita Medical is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Avita Medical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.42% of the float of Avita Medical has been sold short.Short Interest Ratio / Days to CoverAvita Medical has a short interest ratio ("days to cover") of 20.65, which indicates bearish sentiment.Change versus previous monthShort interest in Avita Medical has recently decreased by 4.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvita Medical does not currently pay a dividend.Dividend GrowthAvita Medical does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.34 News SentimentAvita Medical has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avita Medical this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Avita Medical to their MarketBeat watchlist in the last 30 days. Company Ownership2.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $12,450.00 in company stock, which represents 0.0093% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Avita Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,450.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.80% of the stock of Avita Medical is held by insiders.Percentage Held by Institutions27.66% of the stock of Avita Medical is held by institutions.Read more about Avita Medical's insider trading history. Receive RCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avita Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCEL Stock News HeadlinesAvita Medical Inc. (NASDAQ:RCEL) Given Consensus Recommendation of "Hold" by BrokeragesMay 11 at 2:14 AM | americanbankingnews.comAVITA Medical Names Cary Vance as Chief Executive OfficerApril 30, 2026 | globenewswire.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 11 at 1:00 AM | Brownstone Research (Ad)AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GOApril 29, 2026 | globenewswire.comAVITA Medical to Announce First Quarter 2026 Financial ResultsApril 23, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCELApril 21, 2026 | globenewswire.comAVITA Medical, Inc. (RCEL) Shareholder/Analyst Call TranscriptApril 16, 2026 | seekingalpha.comAVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn AssociationApril 15, 2026 | globenewswire.comSee More Headlines RCEL Stock Analysis - Frequently Asked Questions How have RCEL shares performed this year? Avita Medical's stock was trading at $3.45 at the beginning of 2026. Since then, RCEL shares have increased by 26.7% and is now trading at $4.37. How were Avita Medical's earnings last quarter? Avita Medical Inc. (NASDAQ:RCEL) announced its earnings results on Thursday, November, 6th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.03. The company earned $17.06 million during the quarter, compared to analysts' expectations of $29.39 million. Read the conference call transcript. Who are Avita Medical's major shareholders? Top institutional investors of Avita Medical include Thompson Davis & CO. Inc. (0.13%), Abel Hall LLC (0.05%) and R Squared Ltd (0.05%). Insiders that own company stock include David D O'toole, Robert Mcnamara, Donna Shiroma, Suzanne Crowe, Jeremy Curnock Cook and James Corbett. View institutional ownership trends. How do I buy shares of Avita Medical? Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avita Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avita Medical investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Tesla (TSLA). Company Calendar Last Earnings11/06/2025Today5/11/2026Next Earnings (Estimated)5/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RCEL's financial health is in the Green zone, according to TradeSmith. RCEL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:RCEL CIK1762303 Webwww.avitamedical.com Phone(833) 462-8482FaxN/AEmployees130Year Founded1992Price Target and Rating Average Price Target for Avita Medical$6.63 High Price Target$10.00 Low Price Target$3.00 Potential Upside/Downside+51.6%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.59 million Net Margins-67.85% Pretax Margin-67.83% Return on EquityN/A Return on Assets-78.43% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.46 Sales & Book Value Annual Sales$71.61 million Price / Sales1.88 Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-7.95Miscellaneous Outstanding Shares30,780,000Free Float29,915,000Market Cap$134.51 million OptionableOptionable Beta1.90 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:RCEL) was last updated on 5/11/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avita Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avita Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
